(12) **Translation of European patent specification**

(11) **NO/EP 3456717 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 401/14 (2006.01)
A61K 31/4709 (2006.01)
A61P 29/00 (2006.01)
A61P 35/00 (2006.01)
C07D 401/12 (2006.01)
C07D 405/14 (2006.01)
C07D 409/14 (2006.01)
C07D 413/14 (2006.01)
C07D 417/14 (2006.01)
C07D 471/04 (2006.01)
C07D 495/04 (2006.01)
C07D 498/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.07.26
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.03.17
(86)	European Application Nr.	18186568.4
(86)	European Filing Date	2016.06.30
(87)	The European Application's Publication Date	2019.03.20
(30)	Priority	2015.07.06, US, 201562189158 P 2015.12.17, US, 201562269060 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3191470, 2016.06.30
(73)	Proprietor	GILEAD SCIENCES, INC., 333 Lakeside Drive, Foster City,California 94404, USA
(72)	Inventor	BACON, Elizabeth, M., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA BALAN, Gayatri, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA CHOU, Chien-Hung, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA CLARK, Christopher, T., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA COTTELL, Jeromy, J., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA KIM, Musong, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA KIRSCHBERG, Thorsten, A., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA

LINK, John, O., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
PHILLIPS, Gary, c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
SCHROEDER, Scott, D., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
SQUIRES, Neil, H., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
STEVENS, Kirk, L., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
TAYLOR, James, G., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
WATKINS, William, J., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
WRIGHT, Nathan, E., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA
ZIPFEL, Sheila, M., c/o Gilead Sciences, Inc.333 Lakeside Drive, Foster City, CA California 94404, USA

(74) Agent or Attorney OSLO PATENTKONTOR AS, Hoffsveien 1A, 0275 OSLO, Norge

---

(54) Title **4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE**

(56) References Cited:
WO-A1-98/43960
KAILA ET AL: "Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonit riles", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 19, 4 July 2007 (2007-07-04), pages 6425-6442, XP022192446, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2007.06.054
WU J ET AL: "Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 19, no. 13, 7 May 2009 (2009-05-07), pages 3485-3488, XP026155092, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2009.05.009 [retrieved on 2009-05-07]
RAKESH K GOYAL ET AL: "Models for anti-inflammatory activity of 8-substituted-4-anilino-6-aminoquinoline-3 -carbonitriles", MEDICINAL CHEMISTRY RESEARCH, BIRKHÄUSER-VERLAG, BOSTON, vol. 21, no. 7, 19 March 2011 (2011-03-19) , pages 1044 -1055, XP035060999, ISSN: 1554 -8120, DOI: 10.1007/S00044 -011-9613-5
NEAL GREEN ET AL: "Inhibitors of Tumor Progression Loci-2 (Tpl2) Kinase and Tumor Necrosis Factor [alpha] (TNF-[alpha]) Production: Selectivity and in Vivo Antiinflammatory Activity of Novel 8-Substituted-4-anilino-6-aminoquinoline-3 -carbonitriles", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 19, 2007, pages 4728-4745, XP055294201, US ISSN: 0022-2623, DOI: 10.1021/jm070436q

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse av formel (A):



(A).

2. Forbindelse av formel (B)



(B).

3. Fremgangsmåte for fremstilling av en forbindelse av formel (A):



(A).

omfattende trinnene:

(i) å kontakte en forbindelse av formel (C)



(C)

Med en forbindelse av formel (B):


(B)

for å danne en blanding og

(ii) kombinere blandingen med $Pd(PPh_3)_2Cl_2$.

4. Fremgangsmåte ifølge krav 3, hvor trinn (i) utføres ved å løse opp forbindelsene for formel (C) og (B) sammen med kobber(I) jodid i metyl-tetrahydrofuran (Me-THF).

5. Fremgangsmåte ifølge krav 3 eller 4, hvor fremgangsmåten omfatter det følgende trinn (iii) som utføres etter trinn (ii):

(iii) tilsetning av dietylamin.

6. Fremgangsmåte ifølge et hvilket som helst av kravene 3 til 5, hvor fremgangsmåten omfatter det følgende trinn (iv) som utføres etter trinn (iii), om til stede, eller etter trinn (ii) dersom trinn (iii) ikke er til stede:

(iv) oppvarming av reaksjonen til 80°C i en time og

så fortynne med EtOAc og saltlake.

7. Forbindelse av formel (E)


(E).